Phibro Animal Health (PAHC) Financials

$17.29 +0.46 (+2.73%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$17.29 0.00 (0.00%)

As of 04/17/2025 04:19 PM Eastern

Annual Income Statements for Phibro Animal Health

This table shows Phibro Animal Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-3.13	60	83	65	65	55	34	54	49	33	2.42
Consolidated Net Income / (Loss)	-3.13	60	83	65	65	55	34	54	49	33	2.42
Net Income / (Loss) Continuing Operations	-3.13	60	83	65	65	55	34	54	49	33	2.42
Total Pre-Tax Income	6.31	79	77	81	88	72	56	66	72	54	11
Total Operating Income	64	88	86	98	99	83	69	75	79	72	53
Total Gross Profit	204	233	239	248	267	265	257	271	285	298	313
Total Revenue	692	749	752	764	820	828	800	833	942	978	1,018
Operating Revenue	692	749	752	764	820	828	800	833	942	978	1,018
Total Cost of Revenue	488	515	512	516	553	563	543	562	657	680	705
Operating Cost of Revenue	488	515	512	516	553	563	543	562	657	680	705
Total Operating Expenses	141	146	153	150	168	181	188	197	206	226	260
Selling, General & Admin Expense	141	146	153	150	168	181	188	197	206	226	260
Total Other Income / (Expense), net	-57	-8.91	-8.98	-17	-11	-12	-14	-8.40	-6.66	-18	-42
Interest & Investment Income	-	-	-	-	-	-	-	-	-12	-15	-19
Other Income / (Expense), net	-1.75	5.40	7.61	0.11	1.05	0.06	-0.83	4.48	5.22	-2.46	-24
Income Tax Expense	9.44	18	-5.97	16	23	17	22	12	23	21	8.50
Basic Earnings per Share	($0.10)	$1.55	$2.11	$1.63	$1.61	$1.35	$0.83	$1.34	$1.21	$0.81	$0.06
Weighted Average Basic Shares Outstanding	32.19M	38.97M	39.25M	39.52M	40.18M	40.41M	40.45M	40.47M	40.50M	40.50M	40.50M
Diluted Earnings per Share	($0.10)	$1.51	$2.07	$1.61	$1.61	$1.35	$0.83	$1.34	$1.21	$0.81	$0.06
Weighted Average Diluted Shares Outstanding	32.19M	39.82M	39.96M	40.04M	40.39M	40.52M	40.50M	40.50M	40.50M	40.50M	40.52M
Weighted Average Basic & Diluted Shares Outstanding	31.30M	38.90M	39.20M	39.60M	40.30M	40.45M	40.45M	40.50M	40.50M	40.50M	40.50M
Cash Dividends to Common per Share	$0.82	$0.40	$0.40	$0.40	$0.40	$0.46	$0.48	$0.48	$0.48	$0.48	$0.48

This table shows Phibro Animal Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Net Income / (Loss) Attributable to Common Shareholders	7.49	3.86	7.21	10	11	-8.02	1.27	8.41	0.75	6.98	3.19
Consolidated Net Income / (Loss)	7.49	3.86	7.21	10	11	-8.02	1.27	8.41	0.75	6.98	3.19
Net Income / (Loss) Continuing Operations	7.49	3.86	7.21	10	11	-8.02	1.27	8.41	0.75	6.98	3.19
Total Pre-Tax Income	12	5.42	12	15	21	-12	3.57	13	6.41	9.62	4.84
Total Operating Income	23	14	16	19	24	-0.73	16	20	18	18	26
Total Gross Profit	78	69	77	76	77	68	79	80	87	83	102
Total Revenue	255	233	245	246	255	231	250	263	273	260	309
Operating Revenue	255	233	245	246	255	231	250	263	273	260	309
Total Cost of Revenue	177	164	167	170	178	164	171	184	186	177	207
Operating Cost of Revenue	177	164	167	170	178	164	171	184	186	177	207
Total Operating Expenses	56	55	62	57	53	68	63	60	69	66	76
Selling, General & Admin Expense	56	55	62	57	53	68	63	60	69	66	76
Total Other Income / (Expense), net	-11	-8.27	-3.74	-3.45	-2.33	-11	-12	-7.00	-12	-8.08	-21
Interest & Investment Income	-	-	-	-	-	-4.56	-4.66	-	-	-7.64	-9.00
Other Income / (Expense), net	-7.41	-5.20	0.15	0.42	2.17	-6.69	-7.48	-2.43	-7.27	-0.44	-12
Income Tax Expense	4.88	1.56	4.90	5.06	9.94	-3.96	2.29	4.52	5.66	2.65	1.65
Basic Earnings per Share	$0.18	$0.10	$0.18	$0.25	$0.28	($0.20)	$0.03	$0.21	$0.02	$0.17	$0.08
Weighted Average Basic Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Diluted Earnings per Share	$0.18	$0.10	$0.18	$0.25	$0.28	($0.20)	$0.03	$0.21	$0.02	$0.17	$0.08
Weighted Average Diluted Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.52M	40.52M	40.58M	40.72M
Weighted Average Basic & Diluted Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Cash Dividends to Common per Share	-	$0.12	$0.12	$0.12	-	$0.12	$0.12	$0.12	-	$0.12	$0.12

This table details how cash moves in and out of Phibro Animal Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-16	17	4.39	22	-27	28	-21	14	24	-33	29
Net Cash From Operating Activities	-0.71	69	37	98	70	47	59	48	32	13	88
Net Cash From Continuing Operating Activities	-0.71	69	37	98	70	47	59	48	32	13	88
Net Income / (Loss) Continuing Operations	-3.13	60	83	65	65	55	34	54	49	33	2.42
Consolidated Net Income / (Loss)	-3.13	60	83	65	65	55	34	54	49	33	2.42
Depreciation Expense	21	22	23	26	27	28	32	32	33	34	36
Amortization Expense	1.45	0.97	0.99	1.02	0.88	0.88	0.88	0.83	0.59	0.73	1.04
Non-Cash Adjustments To Reconcile Net Income	6.46	-1.96	-1.65	6.28	4.79	0.06	-1.90	-6.75	-5.38	-10	27
Changes in Operating Assets and Liabilities, net	-27	-12	-68	0.48	-27	-36	-5.53	-32	-45	-44	21
Net Cash From Investing Activities	-19	-34	-83	-22	-85	-14	-120	-19	-23	-74	-48
Net Cash From Continuing Investing Activities	-19	-34	-83	-22	-85	-14	-120	-19	-23	-74	-48
Purchase of Property, Plant & Equipment	-20	-20	-36	-21	-19	-30	-34	-29	-37	-52	-41
Acquisitions	-	-10	-47	-	-15	-9.84	-55	0.00	-14	0.00	-3.28
Purchase of Investments	-	-	-	-	-82	-34	-80	-74	-64	-40	-66
Sale and/or Maturity of Investments	-	-	-	-	32	60	49	86	91	17	62
Other Investing Activities, net	0.43	-4.03	0.14	-1.06	-1.06	-0.40	-0.80	-1.26	0.62	0.78	0.33
Net Cash From Financing Activities	4.78	-15	50	-54	-12	-4.11	41	-17	16	27	-6.77
Net Cash From Continuing Financing Activities	4.78	-15	50	-54	-12	-4.11	41	-17	16	27	-6.77
Repayment of Debt	-549	-39	-193	-524	-226	-203	-183	-298	-256	-280	-263
Payment of Dividends	-25	-16	-16	-16	-16	-19	-19	-19	-19	-19	-19
Issuance of Debt	465	38	256	481	225	217	243	300	297	326	276
Other Financing Activities, net	-	-	-	-	-	-	0.00	0.00	-4.84	0.00	0.00
Effect of Exchange Rate Changes	-0.20	-1.49	-0.42	-0.23	-0.54	-0.52	-1.12	1.14	-1.37	0.75	-3.30
Cash Interest Paid	45	13	14	15	11	12	12	11	11	15	17
Cash Income Taxes Paid	12	11	17	15	15	16	21	19	18	20	15

This table details how cash moves in and out of Phibro Animal Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Net Change in Cash & Equivalents	3.50	2.03	-7.86	-31	4.04	1.87	-10	17	20	-19	15
Net Cash From Operating Activities	1.57	-11	-2.49	6.26	20	16	32	11	28	13	3.08
Net Cash From Continuing Operating Activities	1.57	-11	-2.49	6.26	20	16	32	11	28	13	3.08
Net Income / (Loss) Continuing Operations	7.49	3.86	7.21	10	11	-8.02	1.27	8.41	0.75	6.98	3.19
Consolidated Net Income / (Loss)	7.49	3.86	7.21	10	11	-8.02	1.27	8.41	0.75	6.98	3.19
Depreciation Expense	8.41	8.45	8.50	8.49	8.57	8.87	8.91	9.20	9.20	9.00	12
Amortization Expense	0.15	0.15	0.18	0.19	0.21	0.26	0.26	0.26	0.26	0.37	0.50
Non-Cash Adjustments To Reconcile Net Income	8.96	3.06	-4.64	-4.65	-3.84	15	5.53	4.12	2.56	-0.80	13
Changes in Operating Assets and Liabilities, net	-23	-26	-14	-7.81	3.79	0.40	16	-11	16	-2.93	-25
Net Cash From Investing Activities	-9.54	-16	-9.81	-38	-10	-15	-25	1.13	-9.11	-2.93	-260
Net Cash From Continuing Investing Activities	-9.54	-16	-9.81	-38	-10	-15	-25	1.13	-9.11	-2.93	-260
Purchase of Property, Plant & Equipment	-12	-23	-9.82	-7.91	-11	-7.48	-11	-9.73	-13	-9.58	-7.82
Sale and/or Maturity of Investments	15	7.00	10	-	-	9.00	31	17	4.52	6.00	38
Other Investing Activities, net	-0.03	0.03	0.01	0.13	0.61	0.12	0.95	-0.18	-0.56	0.65	0.17
Net Cash From Financing Activities	12	29	3.72	0.28	-6.33	1.30	-15	4.85	1.79	-29	276
Net Cash From Continuing Financing Activities	12	29	3.72	0.28	-6.33	1.30	-15	4.85	1.79	-29	276
Repayment of Debt	-65	-40	-126	-27	-86	-43	-50	-56	-114	-589	-198
Payment of Dividends	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86
Issuance of Debt	82	74	135	32	85	51	42	62	121	567	481
Other Financing Activities, net	-	0.00	-	-	-	-1.74	-1.74	-	-	-1.95	-1.95
Effect of Exchange Rate Changes	-0.92	-0.44	0.73	0.05	0.42	-0.27	-2.18	-0.14	-0.72	0.73	-3.69

This table presents Phibro Animal Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	472	493	608	623	672	727	784	841	932	971	982
Total Current Assets	299	314	343	364	415	466	452	499	566	586	601
Cash & Equivalents	12	29	34	56	29	58	36	50	74	41	71
Short-Term Investments	-	-	-	-	50	24	55	43	17	40	44
Accounts Receivable	114	111	124	126	136	159	127	147	167	163	169
Inventories, net	143	150	168	161	178	198	197	216	259	278	266
Other Current Assets	-	24	18	21	22	27	37	43	49	63	51
Plant, Property, & Equipment, net	109	104	127	127	130	140	148	155	165	196	203
Total Noncurrent Assets	64	75	138	132	126	120	184	188	200	190	178
Goodwill	-	13	21	24	27	27	53	53	53	53	55
Intangible Assets	30	37	60	55	52	47	71	62	64	55	45
Other Noncurrent Operating Assets	34	25	56	54	47	45	60	73	83	82	78
Total Liabilities & Shareholders' Equity	472	493	608	623	672	727	784	841	932	971	982
Total Liabilities	457	464	517	472	487	511	596	603	669	689	726
Total Current Liabilities	112	111	109	116	143	154	157	164	191	176	204
Short-Term Debt	2.97	2.81	2.91	6.25	13	13	19	9.38	15	22	30
Accounts Payable	60	63	60	57	59	73	66	68	96	74	86
Accrued Expenses	50	45	46	53	71	68	72	86	80	80	89
Total Noncurrent Liabilities	345	352	409	356	344	356	439	439	478	513	521
Long-Term Debt	286	287	347	307	300	314	368	383	418	453	458
Other Noncurrent Operating Liabilities	58	66	61	50	44	43	70	56	61	60	63
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	15	30	90	151	185	216	188	239	262	283	257
Total Preferred & Common Equity	15	30	90	151	185	216	188	239	262	283	257
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	0.00
Total Common Equity	15	30	90	151	185	216	188	239	262	283	257
Common Stock	132	118	118	124	130	133	136	136	136	136	136
Retained Earnings	-97	-37	34	83	132	169	183	218	248	261	244
Accumulated Other Comprehensive Income / (Loss)	-20	-52	-62	-55	-76	-86	-130	-115	-121	-114	-124

This table presents Phibro Animal Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Total Assets	916	948	962	965	965	973	979	966	1,286
Total Current Assets	546	570	582	585	584	587	597	571	746
Cash & Equivalents	71	76	68	37	43	33	50	52	67
Short-Term Investments	22	10	10	40	48	60	49	38	0.00
Accounts Receivable	157	143	152	153	149	151	161	161	192
Inventories, net	250	281	289	293	279	287	282	273	427
Other Current Assets	47	60	62	63	65	57	55	48	60
Plant, Property, & Equipment, net	162	179	186	189	193	201	202	206	338
Total Noncurrent Assets	207	199	194	191	187	185	180	189	202
Goodwill	53	53	53	53	53	55	55	55	55
Intangible Assets	67	61	59	57	52	51	48	43	40
Other Noncurrent Operating Assets	87	85	82	81	81	80	77	92	107
Total Liabilities & Shareholders' Equity	916	948	962	965	965	973	979	966	1,286
Total Liabilities	649	686	693	693	691	702	709	708	1,039
Total Current Liabilities	187	172	168	165	172	188	189	177	233
Short-Term Debt	15	15	15	15	24	26	30	7.50	16
Accounts Payable	90	88	80	76	77	86	83	87	99
Accrued Expenses	82	69	72	74	71	75	77	83	118
Total Noncurrent Liabilities	462	513	526	528	519	514	520	531	805
Long-Term Debt	401	452	461	466	459	449	456	467	737
Other Noncurrent Operating Liabilities	62	61	65	62	60	65	64	64	69
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	267	263	268	272	273	271	270	259	247
Total Preferred & Common Equity	267	263	268	272	273	271	270	259	247
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	267	263	268	272	273	271	270	259	247
Common Stock	136	136	136	136	136	136	136	136	137
Retained Earnings	245	247	249	254	248	244	248	246	244
Accumulated Other Comprehensive Income / (Loss)	-114	-120	-117	-118	-111	-110	-114	-124	-134

This table displays calculated financial ratios and metrics derived from Phibro Animal Health's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.93%	8.19%	0.39%	1.70%	7.29%	0.98%	-3.34%	4.12%	13.07%	3.78%	4.07%
EBITDA Growth	14.13%	36.14%	1.86%	6.17%	2.19%	-12.58%	-9.07%	10.31%	4.85%	-11.38%	-35.97%
EBIT Growth	16.01%	50.01%	0.31%	5.03%	1.97%	-16.70%	-17.91%	16.06%	6.12%	-17.59%	-57.56%
NOPAT Growth	-139.97%	312.17%	37.73%	-14.98%	-7.24%	-12.62%	-34.33%	46.47%	-12.33%	-19.32%	-72.76%
Net Income Growth	-112.56%	2,027.73%	37.24%	-21.89%	0.41%	-15.67%	-38.68%	62.09%	-9.58%	-33.69%	-92.59%
EPS Growth	-112.20%	1,610.00%	37.09%	-22.22%	0.00%	-16.15%	-38.52%	61.45%	-9.70%	-33.06%	-92.59%
Operating Cash Flow Growth	83.58%	9,749.44%	-45.83%	164.35%	-28.84%	-32.62%	25.82%	-18.61%	-34.48%	-57.95%	558.11%
Free Cash Flow Firm Growth	71.06%	226.96%	-135.36%	413.26%	-18.70%	-66.26%	-12.53%	-58.41%	-268.50%	-119.91%	301.79%
Invested Capital Growth	8.70%	-0.95%	40.39%	0.29%	2.44%	10.15%	5.05%	11.06%	12.41%	11.91%	-6.80%
Revenue Q/Q Growth	0.00%	0.17%	0.57%	0.75%	2.11%	-0.95%	-2.20%	4.31%	3.86%	-0.02%	1.81%
EBITDA Q/Q Growth	0.00%	5.38%	3.69%	0.06%	2.96%	-10.93%	8.47%	0.44%	-3.32%	11.45%	-17.48%
EBIT Q/Q Growth	0.00%	7.03%	3.38%	0.46%	3.30%	-14.34%	11.28%	1.10%	-5.15%	17.76%	-33.44%
NOPAT Q/Q Growth	0.00%	22.16%	2.09%	4.91%	6.39%	-17.38%	-12.83%	29.03%	-7.68%	-3.93%	-60.34%
Net Income Q/Q Growth	0.00%	87.01%	6.18%	0.25%	11.59%	-19.58%	-8.61%	26.75%	-16.38%	14.03%	-81.64%
EPS Q/Q Growth	0.00%	122.06%	7.25%	-1.23%	13.38%	-20.12%	-7.78%	25.23%	-16.55%	14.08%	-81.25%
Operating Cash Flow Q/Q Growth	-103.81%	110.75%	14.56%	-11.68%	-4.72%	11.25%	-15.64%	-1.64%	-4.51%	348.60%	10.32%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	22.48%	-11.25%	29.21%	-44.68%	-26.92%	-69.19%	54.34%	31.39%	17.58%
Invested Capital Q/Q Growth	0.00%	0.15%	-1.18%	2.16%	-0.29%	0.56%	0.67%	6.83%	2.44%	-0.07%	-4.12%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	29.54%	31.16%	31.81%	32.48%	32.55%	31.96%	32.10%	32.56%	30.29%	30.50%	30.77%
EBITDA Margin	12.28%	15.45%	15.67%	16.36%	15.59%	13.49%	12.69%	13.45%	12.47%	10.65%	6.55%
Operating Margin	9.22%	11.71%	11.41%	12.81%	12.06%	10.05%	8.65%	8.98%	8.38%	7.35%	5.24%
EBIT Margin	8.97%	12.43%	12.42%	12.83%	12.19%	10.06%	8.54%	9.52%	8.94%	7.10%	2.89%
Profit (Net Income) Margin	-0.45%	8.05%	11.01%	8.45%	7.91%	6.61%	4.19%	6.53%	5.22%	3.33%	0.24%
Tax Burden Percent	-49.57%	76.53%	107.77%	80.22%	73.67%	76.52%	60.44%	81.82%	67.99%	60.30%	22.13%
Interest Burden Percent	10.17%	84.63%	82.23%	82.15%	88.09%	85.86%	81.20%	83.77%	85.90%	77.92%	37.06%
Effective Tax Rate	149.57%	23.47%	-7.77%	19.78%	26.33%	23.48%	39.56%	18.18%	32.01%	39.70%	77.87%
Return on Invested Capital (ROIC)	-11.25%	23.03%	26.52%	19.27%	17.64%	14.49%	8.86%	12.00%	9.41%	6.77%	1.81%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.00%	20.50%	23.16%	14.41%	14.38%	10.74%	5.79%	9.68%	8.00%	3.85%	-0.64%
Return on Net Nonoperating Assets (RNNOA)	22.88%	246.21%	111.24%	34.21%	20.97%	12.80%	7.75%	13.49%	10.22%	5.20%	-0.91%
Return on Equity (ROE)	11.63%	269.25%	137.76%	53.48%	38.61%	27.29%	16.60%	25.49%	19.63%	11.97%	0.90%
Cash Return on Invested Capital (CROIC)	-19.59%	23.99%	-7.09%	18.99%	15.23%	4.83%	3.93%	1.51%	-2.28%	-4.47%	8.84%
Operating Return on Assets (OROA)	13.11%	19.28%	16.96%	15.93%	15.44%	11.91%	9.05%	9.76%	9.50%	7.29%	3.02%
Return on Assets (ROA)	-0.66%	12.49%	15.03%	10.50%	10.02%	7.83%	4.44%	6.69%	5.55%	3.43%	0.25%
Return on Common Equity (ROCE)	11.63%	269.25%	137.76%	53.48%	38.61%	27.29%	16.60%	25.49%	19.63%	11.97%	0.90%
Return on Equity Simple (ROE_SIMPLE)	-20.64%	203.46%	91.43%	42.75%	35.08%	25.33%	17.83%	22.80%	18.74%	11.54%	0.94%
Net Operating Profit after Tax (NOPAT)	-32	67	92	79	73	64	42	61	54	43	12
NOPAT Margin	-4.57%	8.96%	12.30%	10.28%	8.89%	7.69%	5.23%	7.35%	5.70%	4.43%	1.16%
Net Nonoperating Expense Percent (NNEP)	-9.26%	2.53%	3.36%	4.86%	3.26%	3.75%	3.06%	2.31%	1.41%	2.92%	2.45%
Cost of Revenue to Revenue	70.46%	68.84%	68.19%	67.52%	67.45%	68.04%	67.90%	67.44%	69.71%	69.50%	69.23%
SG&A Expenses to Revenue	20.32%	19.45%	20.40%	19.67%	20.48%	21.91%	23.45%	23.58%	21.91%	23.15%	25.53%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	20.32%	19.45%	20.40%	19.67%	20.48%	21.91%	23.45%	23.58%	21.91%	23.15%	25.53%
Earnings before Interest and Taxes (EBIT)	62	93	93	98	100	83	68	79	84	69	29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	85	116	118	125	128	112	102	112	117	104	67
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	45.93	42.50	6.83	8.29	8.65	5.20	5.04	4.47	2.75	1.90	2.65
Price to Tangible Book Value (P/TBV)	0.00	0.00	66.76	17.26	15.15	7.95	14.69	8.63	4.97	3.07	4.33
Price to Revenue (P/Rev)	1.01	1.68	0.82	1.64	1.95	1.36	1.18	1.28	0.77	0.55	0.67
Price to Earnings (P/E)	0.00	20.89	7.48	19.38	24.66	20.53	28.25	19.60	14.68	16.42	281.14
Dividend Yield	0.00%	1.24%	2.55%	1.27%	1.01%	1.66%	2.05%	1.82%	2.69%	3.63%	2.86%
Earnings Yield	0.00%	4.79%	13.38%	5.16%	4.05%	4.87%	3.54%	5.10%	6.81%	6.09%	0.36%
Enterprise Value to Invested Capital (EV/IC)	3.33	5.24	2.30	3.70	4.38	2.97	2.57	2.54	1.76	1.37	1.67
Enterprise Value to Revenue (EV/Rev)	1.41	2.03	1.24	1.98	2.24	1.65	1.55	1.64	1.13	0.95	1.03
Enterprise Value to EBITDA (EV/EBITDA)	11.46	13.14	7.94	12.07	14.35	12.24	12.24	12.18	9.05	8.92	15.79
Enterprise Value to EBIT (EV/EBIT)	15.69	16.33	10.02	15.40	18.34	16.42	18.19	17.20	12.63	13.39	35.74
Enterprise Value to NOPAT (EV/NOPAT)	0.00	22.64	10.12	19.21	25.16	21.48	29.73	22.28	19.81	21.44	89.21
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	22.11	25.12	15.34	26.19	29.00	20.95	28.25	33.61	69.79	12.02
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	21.74	0.00	19.50	29.14	64.42	66.95	176.70	0.00	0.00	18.23
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	19.10	9.77	3.87	2.07	1.69	1.51	2.06	1.64	1.65	1.68	1.90
Long-Term Debt to Equity	18.91	9.68	3.84	2.03	1.62	1.45	1.96	1.60	1.59	1.60	1.79
Financial Leverage	-11.45	12.01	4.80	2.37	1.46	1.19	1.34	1.39	1.28	1.35	1.42
Leverage Ratio	-17.60	21.57	9.17	5.10	3.85	3.49	3.74	3.81	3.54	3.49	3.62
Compound Leverage Factor	-1.79	18.25	7.54	4.19	3.39	2.99	3.03	3.19	3.04	2.72	1.34
Debt to Total Capital	95.03%	90.72%	79.47%	67.44%	62.81%	60.16%	67.28%	62.18%	62.26%	62.70%	65.54%
Short-Term Debt to Total Capital	0.97%	0.88%	0.66%	1.35%	2.53%	2.31%	3.26%	1.49%	2.16%	2.94%	4.00%
Long-Term Debt to Total Capital	94.05%	89.84%	78.81%	66.10%	60.28%	57.85%	64.02%	60.69%	60.10%	59.75%	61.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	4.97%	9.28%	20.53%	32.56%	37.19%	39.84%	32.72%	37.82%	37.74%	37.30%	34.46%
Debt to EBITDA	3.41	2.50	2.97	2.50	2.44	2.92	3.81	3.50	3.68	4.56	7.32
Net Debt to EBITDA	3.27	2.25	2.69	2.06	1.82	2.19	2.91	2.67	2.91	3.78	5.60
Long-Term Debt to EBITDA	3.37	2.48	2.95	2.45	2.35	2.81	3.62	3.42	3.56	4.35	6.87
Debt to NOPAT	-9.15	4.32	3.79	3.99	4.29	5.12	9.25	6.40	8.06	10.96	41.36
Net Debt to NOPAT	-8.78	3.88	3.43	3.27	3.20	3.84	7.07	4.88	6.36	9.08	31.65
Long-Term Debt to NOPAT	-9.06	4.27	3.76	3.91	4.11	4.93	8.81	6.25	7.78	10.45	38.84
Altman Z-Score	3.00	4.16	3.00	4.00	4.45	3.68	3.04	3.20	2.81	2.59	2.53
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.66	2.82	3.15	3.14	2.90	3.02	2.87	3.04	2.97	3.33	2.94
Quick Ratio	1.12	1.26	1.45	1.57	1.50	1.56	1.39	1.46	1.35	1.39	1.39
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-55	70	-25	77	63	21	19	7.72	-13	-29	58
Operating Cash Flow to CapEx	-3.59%	342.53%	102.38%	471.19%	377.44%	157.80%	174.32%	164.75%	85.44%	25.70%	212.41%
Free Cash Flow to Firm to Interest Expense	-0.99	4.89	-1.49	4.42	5.28	1.80	1.44	0.60	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-0.01	4.80	2.24	5.62	5.88	4.01	4.62	3.75	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-0.37	3.40	0.05	4.43	4.32	1.47	1.97	1.47	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.46	1.55	1.37	1.24	1.27	1.18	1.06	1.03	1.06	1.03	1.04
Accounts Receivable Turnover	6.50	6.66	6.40	6.12	6.27	5.62	5.61	6.10	6.01	5.93	6.11
Inventory Turnover	3.44	3.52	3.23	3.14	3.26	2.99	2.75	2.72	2.76	2.53	2.59
Fixed Asset Turnover	6.48	7.01	6.49	6.00	6.37	6.13	5.55	5.50	5.89	5.42	5.10
Accounts Payable Turnover	8.30	8.40	8.32	8.82	9.50	8.49	7.80	8.36	8.01	8.02	8.84
Days Sales Outstanding (DSO)	56.18	54.84	57.04	59.61	58.22	64.97	65.11	59.87	60.70	61.59	59.70
Days Inventory Outstanding (DIO)	106.02	103.76	113.05	116.33	111.99	121.96	132.64	134.11	132.10	144.12	140.77
Days Payable Outstanding (DPO)	43.99	43.44	43.88	41.40	38.40	42.98	46.77	43.66	45.55	45.50	41.29
Cash Conversion Cycle (CCC)	118.21	115.16	126.21	134.54	131.80	143.95	150.98	150.32	147.25	160.21	159.18
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	293	290	407	408	418	461	484	537	604	676	630
Invested Capital Turnover	2.46	2.57	2.16	1.87	1.98	1.88	1.69	1.63	1.65	1.53	1.56
Increase / (Decrease) in Invested Capital	23	-2.79	117	1.17	9.95	42	23	54	67	72	-46
Enterprise Value (EV)	973	1,519	935	1,510	1,834	1,368	1,243	1,365	1,064	929	1,053
Market Capitalization	696	1,259	618	1,252	1,600	1,123	948	1,066	722	535	679
Book Value per Share	$0.39	$0.76	$2.30	$3.81	$4.59	$5.34	$4.65	$5.89	$6.48	$6.97	$6.34
Tangible Book Value per Share	($0.38)	($0.52)	$0.24	$1.83	$2.62	$3.49	$1.60	$3.05	$3.59	$4.30	$3.88
Total Capital	305	319	441	464	497	542	575	631	695	757	745
Total Debt	289	290	350	313	312	326	387	392	433	475	488
Total Long-Term Debt	286	287	347	307	300	314	368	383	418	453	458
Net Debt	278	260	317	257	233	245	296	299	342	394	373
Capital Expenditures (CapEx)	20	20	36	21	19	30	34	29	37	52	41
Debt-free, Cash-free Net Working Capital (DFCFNWC)	178	176	203	198	206	243	222	251	299	351	312
Debt-free Net Working Capital (DFNWC)	190	205	237	254	285	324	313	344	390	432	427
Net Working Capital (NWC)	187	202	234	248	272	312	295	335	375	410	397
Net Nonoperating Expense (NNE)	-28	6.82	9.68	14	8.00	8.97	8.27	6.87	4.53	11	9.38
Net Nonoperating Obligations (NNO)	278	260	317	257	233	245	296	299	342	394	373
Total Depreciation and Amortization (D&A)	23	23	24	27	28	28	33	33	33	35	37
Debt-free, Cash-free Net Working Capital to Revenue	25.73%	23.51%	27.06%	25.91%	25.08%	29.34%	27.74%	30.11%	31.75%	35.87%	30.66%
Debt-free Net Working Capital to Revenue	27.43%	27.41%	31.53%	33.25%	34.73%	39.19%	39.15%	41.30%	41.43%	44.18%	41.92%
Net Working Capital to Revenue	27.00%	27.04%	31.14%	32.43%	33.20%	37.67%	36.81%	40.17%	39.84%	41.90%	39.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.10)	$1.55	$2.11	$1.63	$1.61	$1.35	$0.83	$1.34	$1.21	$0.81	$0.06
Adjusted Weighted Average Basic Shares Outstanding	38.96M	38.97M	39.25M	39.52M	40.18M	40.41M	40.45M	40.47M	40.50M	40.50M	40.50M
Adjusted Diluted Earnings per Share	($0.10)	$1.51	$2.07	$1.61	$1.61	$1.35	$0.83	$1.34	$1.21	$0.81	$0.06
Adjusted Weighted Average Diluted Shares Outstanding	38.96M	39.82M	39.96M	40.04M	40.39M	40.52M	40.50M	40.50M	40.50M	40.50M	40.52M
Adjusted Basic & Diluted Earnings per Share	($0.10)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.19M	39.10M	39.41M	39.89M	40.37M	40.45M	40.45M	40.50M	40.50M	40.50M	40.50M
Normalized Net Operating Profit after Tax (NOPAT)	45	67	60	79	73	64	42	61	54	43	37
Normalized NOPAT Margin	6.45%	8.96%	7.99%	10.28%	8.89%	7.69%	5.23%	7.35%	5.70%	4.43%	3.67%
Pre Tax Income Margin	0.91%	10.52%	10.21%	10.54%	10.74%	8.64%	6.94%	7.98%	7.68%	5.53%	1.07%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.11	6.51	5.63	5.60	8.39	7.07	5.32	6.16	0.00	0.00	0.00
NOPAT to Interest Expense	-0.57	4.69	5.57	4.49	6.12	5.41	3.25	4.76	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.76	5.10	3.44	4.41	6.84	4.53	2.67	3.88	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-0.92	3.29	3.38	3.30	4.56	2.87	0.60	2.48	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-799.49%	25.87%	18.99%	24.49%	24.77%	33.98%	57.87%	35.73%	39.54%	59.63%	804.72%
Augmented Payout Ratio	-799.49%	25.87%	18.99%	24.49%	24.77%	33.98%	57.87%	35.73%	39.54%	59.63%	804.72%

This table displays calculated financial ratios and metrics derived from Phibro Animal Health's official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	15.88%	8.32%	5.13%	2.53%	-0.08%	-0.50%	2.17%	7.14%	7.10%	12.57%	23.73%
EBITDA Growth	-14.37%	-16.62%	-28.76%	-27.90%	44.52%	-89.95%	-29.50%	-2.53%	-40.66%	1,451.98%	48.97%
EBIT Growth	-22.80%	-32.04%	-39.61%	-36.24%	67.60%	-187.40%	-48.58%	-7.79%	-57.03%	332.78%	68.22%
NOPAT Growth	-31.90%	-2.11%	-42.99%	-2.51%	-8.00%	-105.22%	-40.52%	5.06%	-83.04%	2,625.13%	199.58%
Net Income Growth	-56.27%	-40.99%	-58.72%	-43.23%	53.57%	-307.86%	-82.33%	-16.30%	-93.46%	187.02%	150.00%
EPS Growth	-57.14%	-37.50%	-58.14%	-43.18%	55.56%	-300.00%	-83.33%	-16.00%	-92.86%	185.00%	166.67%
Operating Cash Flow Growth	-48.73%	-379.98%	-112.37%	2.07%	1,185.77%	251.42%	1,367.90%	82.27%	40.47%	-22.08%	-90.25%
Free Cash Flow Firm Growth	-59.26%	-183.84%	-387.02%	-0.61%	-11.99%	76.59%	116.51%	143.40%	181.27%	260.49%	-1,514.88%
Invested Capital Growth	12.41%	18.88%	22.40%	14.72%	11.91%	3.29%	-1.95%	-2.86%	-6.80%	-3.30%	42.81%
Revenue Q/Q Growth	6.53%	-8.91%	5.21%	0.42%	3.82%	-9.29%	8.04%	5.31%	3.78%	-4.66%	18.75%
EBITDA Q/Q Growth	-37.34%	-28.92%	44.44%	12.08%	25.59%	-95.06%	913.64%	54.96%	-23.54%	29.24%	-2.70%
EBIT Q/Q Growth	-47.99%	-45.18%	88.51%	18.65%	36.71%	-128.59%	210.91%	112.76%	-36.30%	54.86%	-19.85%
NOPAT Q/Q Growth	9.48%	-29.69%	-3.15%	30.75%	3.32%	-103.99%	1,204.09%	130.97%	-83.32%	493.78%	30.99%
Net Income Q/Q Growth	-57.67%	-48.50%	86.98%	39.28%	14.50%	-169.71%	115.90%	559.73%	-91.05%	827.53%	-54.34%
EPS Q/Q Growth	-59.09%	-44.44%	80.00%	38.89%	12.00%	-171.43%	115.00%	600.00%	-90.48%	750.00%	-52.94%
Operating Cash Flow Q/Q Growth	-74.33%	-779.67%	76.73%	351.47%	223.34%	-19.96%	94.81%	-63.85%	149.20%	-55.60%	-75.63%
Free Cash Flow Firm Q/Q Growth	28.59%	-74.98%	-21.61%	33.80%	20.51%	63.42%	185.78%	73.98%	48.86%	-27.76%	-856.21%
Invested Capital Q/Q Growth	2.44%	6.54%	3.50%	1.55%	-0.07%	-1.67%	-1.74%	0.61%	-4.12%	2.02%	45.11%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.72%	29.52%	31.63%	30.75%	30.06%	29.27%	31.45%	30.24%	31.90%	32.06%	32.94%
EBITDA Margin	9.41%	7.35%	10.08%	11.26%	13.62%	0.74%	6.96%	10.24%	7.54%	10.23%	8.38%
Operating Margin	8.97%	5.89%	6.48%	7.55%	9.32%	-0.31%	6.28%	7.57%	6.74%	6.80%	8.26%
EBIT Margin	6.06%	3.65%	6.54%	7.72%	10.17%	-3.21%	3.29%	6.65%	4.08%	6.63%	4.47%
Profit (Net Income) Margin	2.93%	1.66%	2.95%	4.09%	4.51%	-3.46%	0.51%	3.19%	0.28%	2.68%	1.03%
Tax Burden Percent	60.53%	71.18%	59.54%	66.49%	53.63%	66.91%	35.74%	65.04%	11.74%	72.51%	65.83%
Interest Burden Percent	79.92%	63.85%	75.71%	79.60%	82.66%	161.55%	43.35%	73.85%	57.49%	55.73%	34.97%
Effective Tax Rate	39.47%	28.82%	40.46%	33.51%	46.37%	0.00%	64.26%	34.96%	88.26%	27.49%	34.17%
Return on Invested Capital (ROIC)	8.96%	6.79%	6.19%	7.76%	7.63%	-0.33%	3.34%	7.38%	1.23%	7.89%	7.58%
ROIC Less NNEP Spread (ROIC-NNEP)	6.97%	5.08%	5.56%	7.13%	7.29%	-2.27%	2.23%	6.23%	0.87%	6.38%	5.03%
Return on Net Nonoperating Assets (RNNOA)	8.91%	7.06%	7.70%	9.61%	9.84%	-3.27%	3.23%	9.09%	1.23%	9.31%	10.38%
Return on Equity (ROE)	17.87%	13.84%	13.89%	17.36%	17.48%	-3.60%	6.57%	16.47%	2.46%	17.20%	17.97%
Cash Return on Invested Capital (CROIC)	-2.28%	-8.27%	-12.59%	-6.59%	-4.47%	1.73%	6.53%	7.37%	8.84%	9.23%	-29.38%
Operating Return on Assets (OROA)	6.44%	3.93%	7.02%	8.03%	10.45%	-3.27%	3.34%	6.83%	4.25%	7.19%	4.38%
Return on Assets (ROA)	3.12%	1.78%	3.16%	4.25%	4.63%	-3.54%	0.52%	3.28%	0.29%	2.90%	1.01%
Return on Common Equity (ROCE)	17.87%	13.84%	13.89%	17.36%	17.48%	-3.60%	6.57%	16.47%	2.46%	17.20%	17.97%
Return on Equity Simple (ROE_SIMPLE)	0.00%	17.70%	13.50%	10.50%	0.00%	7.59%	5.46%	4.87%	0.00%	6.73%	7.83%
Net Operating Profit after Tax (NOPAT)	14	9.74	9.43	12	13	-0.51	5.61	13	2.16	13	17
NOPAT Margin	5.43%	4.19%	3.86%	5.02%	5.00%	-0.22%	2.24%	4.92%	0.79%	4.93%	5.44%
Net Nonoperating Expense Percent (NNEP)	1.99%	1.71%	0.63%	0.63%	0.34%	1.94%	1.11%	1.15%	0.37%	1.51%	2.55%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	0.75%	-	-	-	1.68%
Cost of Revenue to Revenue	69.28%	70.48%	68.37%	69.25%	69.94%	70.73%	68.55%	69.76%	68.10%	67.94%	67.06%
SG&A Expenses to Revenue	21.76%	23.64%	25.16%	23.20%	20.74%	29.59%	25.17%	22.67%	25.16%	25.26%	24.68%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	21.76%	23.64%	25.16%	23.20%	20.74%	29.59%	25.17%	22.67%	25.16%	25.26%	24.68%
Earnings before Interest and Taxes (EBIT)	15	8.48	16	19	26	-7.42	8.22	17	11	17	14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	24	17	25	28	35	1.72	17	27	21	27	26
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.75	1.92	1.92	2.18	1.90	1.83	1.69	1.93	2.65	3.53	3.45
Price to Tangible Book Value (P/TBV)	4.97	3.41	3.30	3.66	3.07	2.98	2.76	3.11	4.33	5.67	5.58
Price to Revenue (P/Rev)	0.77	0.53	0.53	0.61	0.55	0.51	0.46	0.52	0.67	0.87	0.77
Price to Earnings (P/E)	14.68	10.88	14.22	20.75	16.42	24.12	30.85	39.51	281.14	52.40	44.03
Dividend Yield	2.69%	3.84%	3.77%	3.28%	3.63%	3.89%	4.26%	3.74%	2.86%	2.13%	2.29%
Earnings Yield	6.81%	9.19%	7.03%	4.82%	6.09%	4.15%	3.24%	2.53%	0.36%	1.91%	2.27%
Enterprise Value to Invested Capital (EV/IC)	1.76	1.38	1.37	1.47	1.37	1.34	1.28	1.38	1.67	2.02	1.65
Enterprise Value to Revenue (EV/Rev)	1.13	0.92	0.94	1.02	0.95	0.91	0.85	0.91	1.03	1.24	1.39
Enterprise Value to EBITDA (EV/EBITDA)	9.05	7.77	8.77	10.68	8.92	10.05	10.30	11.23	15.79	14.16	15.35
Enterprise Value to EBIT (EV/EBIT)	12.63	11.05	13.10	16.93	13.39	16.67	18.35	20.50	35.74	23.95	25.72
Enterprise Value to NOPAT (EV/NOPAT)	19.81	16.65	19.96	22.12	21.44	27.47	27.83	30.49	89.21	33.76	32.95
Enterprise Value to Operating Cash Flow (EV/OCF)	33.61	51.76	0.00	0.00	69.79	22.18	11.30	11.42	12.02	15.43	27.67
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	78.76	19.46	18.47	18.23	21.49	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.65	1.78	1.77	1.77	1.68	1.77	1.75	1.80	1.90	1.83	3.05
Long-Term Debt to Equity	1.59	1.72	1.72	1.71	1.60	1.68	1.66	1.69	1.79	1.81	2.99
Financial Leverage	1.28	1.39	1.38	1.35	1.35	1.44	1.45	1.46	1.42	1.46	2.06
Leverage Ratio	3.54	3.60	3.57	3.49	3.49	3.57	3.59	3.58	3.62	3.63	4.36
Compound Leverage Factor	2.83	2.30	2.70	2.78	2.89	5.77	1.56	2.65	2.08	2.02	1.53
Debt to Total Capital	62.26%	64.00%	63.96%	63.87%	62.70%	63.88%	63.68%	64.27%	65.54%	64.72%	75.32%
Short-Term Debt to Total Capital	2.16%	2.11%	2.07%	2.05%	2.94%	3.19%	3.49%	3.94%	4.00%	1.02%	1.63%
Long-Term Debt to Total Capital	60.10%	61.89%	61.89%	61.83%	59.75%	60.68%	60.19%	60.33%	61.54%	63.69%	73.69%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	37.74%	36.00%	36.04%	36.13%	37.30%	36.12%	36.32%	35.73%	34.46%	35.28%	24.68%
Debt to EBITDA	3.68	4.09	4.57	5.15	4.56	5.44	5.83	6.01	7.32	5.18	7.52
Net Debt to EBITDA	2.91	3.34	3.82	4.33	3.78	4.41	4.69	4.79	5.60	4.20	6.85
Long-Term Debt to EBITDA	3.56	3.96	4.43	4.99	4.35	5.17	5.51	5.64	6.87	5.10	7.36
Debt to NOPAT	8.06	8.77	10.41	10.68	10.96	14.87	15.76	16.33	41.36	12.35	16.15
Net Debt to NOPAT	6.36	7.15	8.70	8.96	9.08	12.06	12.69	13.01	31.65	10.01	14.71
Long-Term Debt to NOPAT	7.78	8.48	10.07	10.33	10.45	14.13	14.89	15.32	38.84	12.15	15.80
Altman Z-Score	2.57	2.35	2.39	2.48	2.44	2.29	2.27	2.37	2.47	2.76	2.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.97	3.30	3.47	3.54	3.33	3.39	3.12	3.16	2.94	3.23	3.20
Quick Ratio	1.35	1.33	1.37	1.39	1.39	1.39	1.30	1.37	1.39	1.42	1.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-53	-92	-112	-74	-59	-22	19	32	48	35	-263
Operating Cash Flow to CapEx	13.24%	-46.16%	-25.35%	79.15%	185.82%	216.68%	287.96%	117.23%	217.48%	131.71%	39.33%
Free Cash Flow to Firm to Interest Expense	0.00	-30.16	-28.96	-19.24	0.00	0.00	0.00	7.06	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-3.49	-0.64	1.62	0.00	0.00	0.00	2.49	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-11.04	-3.17	-0.43	0.00	0.00	0.00	0.37	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.06	1.08	1.07	1.04	1.03	1.02	1.02	1.03	1.04	1.08	0.98
Accounts Receivable Turnover	6.01	6.78	6.61	6.32	5.93	6.69	6.49	6.37	6.11	6.75	6.46
Inventory Turnover	2.76	2.67	2.60	2.50	2.53	2.43	2.37	2.42	2.59	2.60	2.11
Fixed Asset Turnover	5.89	5.78	5.71	5.57	5.42	5.24	5.08	5.11	5.10	5.24	4.11
Accounts Payable Turnover	8.01	8.64	8.39	8.20	8.02	8.21	8.19	8.80	8.84	8.77	8.11
Days Sales Outstanding (DSO)	60.70	53.86	55.26	57.71	61.59	54.55	56.21	57.30	59.70	54.05	56.50
Days Inventory Outstanding (DIO)	132.10	136.63	140.33	146.07	144.12	150.43	153.71	150.60	140.77	140.25	172.80
Days Payable Outstanding (DPO)	45.55	42.22	43.51	44.53	45.50	44.48	44.57	41.47	41.29	41.63	44.99
Cash Conversion Cycle (CCC)	147.25	148.27	152.08	159.25	160.21	160.50	165.36	166.42	159.18	152.67	184.31
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	604	644	666	677	676	665	653	657	630	643	933
Invested Capital Turnover	1.65	1.62	1.61	1.54	1.53	1.49	1.49	1.50	1.56	1.60	1.39
Increase / (Decrease) in Invested Capital	67	102	122	87	72	21	-13	-19	-46	-22	280
Enterprise Value (EV)	1,064	887	913	997	929	892	839	907	1,053	1,296	1,537
Market Capitalization	722	506	515	593	535	500	457	520	679	912	851
Book Value per Share	$6.48	$6.49	$6.63	$6.72	$6.97	$6.74	$6.69	$6.67	$6.34	$6.38	$6.09
Tangible Book Value per Share	$3.59	$3.66	$3.85	$4.00	$4.30	$4.14	$4.08	$4.13	$3.88	$3.98	$3.76
Total Capital	695	730	745	754	757	756	746	756	745	733	1,000
Total Debt	433	467	476	481	475	483	475	486	488	474	753
Total Long-Term Debt	418	452	461	466	453	459	449	456	458	467	737
Net Debt	342	381	398	404	394	392	382	387	373	384	686
Capital Expenditures (CapEx)	12	23	9.82	7.91	11	7.48	11	9.73	13	9.58	7.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)	299	327	351	358	351	345	332	339	312	312	462
Debt-free Net Working Capital (DFNWC)	390	413	430	436	432	436	425	438	427	401	529
Net Working Capital (NWC)	375	398	414	420	410	412	399	408	397	394	513
Net Nonoperating Expense (NNE)	6.37	5.88	2.22	2.29	1.25	7.51	4.34	4.55	1.41	5.86	14
Net Nonoperating Obligations (NNO)	342	381	398	404	394	392	382	387	373	384	686
Total Depreciation and Amortization (D&A)	8.55	8.60	8.68	8.68	8.79	9.13	9.17	9.46	9.46	9.37	12
Debt-free, Cash-free Net Working Capital to Revenue	31.75%	34.03%	36.12%	36.64%	35.87%	35.33%	33.85%	33.93%	30.66%	29.76%	41.78%
Debt-free Net Working Capital to Revenue	41.43%	43.02%	44.19%	44.53%	44.18%	44.66%	43.27%	43.81%	41.92%	38.34%	47.84%
Net Working Capital to Revenue	39.84%	41.41%	42.60%	42.96%	41.90%	42.19%	40.62%	40.83%	39.00%	37.63%	46.37%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.18	$0.10	$0.18	$0.25	$0.28	($0.20)	$0.03	$0.21	$0.02	$0.17	$0.08
Adjusted Weighted Average Basic Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Adjusted Diluted Earnings per Share	$0.18	$0.10	$0.18	$0.25	$0.28	($0.20)	$0.03	$0.21	$0.02	$0.17	$0.08
Adjusted Weighted Average Diluted Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.52M	40.52M	40.58M	40.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Normalized Net Operating Profit after Tax (NOPAT)	14	9.74	9.43	12	13	-0.51	11	13	13	13	17
Normalized NOPAT Margin	5.43%	4.19%	3.86%	5.02%	5.00%	-0.22%	4.40%	4.92%	4.72%	4.93%	5.44%
Pre Tax Income Margin	4.85%	2.33%	4.95%	6.15%	8.41%	-5.18%	1.43%	4.91%	2.35%	3.69%	1.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	2.77	4.12	4.90	0.00	0.00	0.00	3.82	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	3.18	2.43	3.19	0.00	0.00	0.00	2.83	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-4.79	1.59	2.86	0.00	0.00	0.00	1.70	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-4.38	-0.10	1.14	0.00	0.00	0.00	0.71	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	39.54%	41.81%	53.64%	67.99%	59.63%	93.76%	131.38%	147.71%	804.72%	111.70%	100.64%
Augmented Payout Ratio	39.54%	41.81%	53.64%	67.99%	59.63%	93.76%	131.38%	147.71%	804.72%	111.70%	100.64%

Frequently Asked Questions About Phibro Animal Health's Financials

When does Phibro Animal Health's fiscal year end?

According to the most recent income statement we have on file, Phibro Animal Health's financial year ends in June. Their financial year 2024 ended on June 30, 2024.

How has Phibro Animal Health's net income changed over the last 10 years?

Phibro Animal Health's net income appears to be on a downward trend, with a most recent value of $2.42 million in 2024, falling from -$3.13 million in 2014. The previous period was $32.61 million in 2023.

What is Phibro Animal Health's operating income?

Phibro Animal Health's total operating income in 2024 was $53.32 million, based on the following breakdown:

Total Gross Profit: $313.09 million
Total Operating Expenses: $259.78 million

How has Phibro Animal Health revenue changed over the last 10 years?

Over the last 10 years, Phibro Animal Health's total revenue changed from $691.91 million in 2014 to $1.02 billion in 2024, a change of 47.1%.

How much debt does Phibro Animal Health have?

Phibro Animal Health's total liabilities were at $725.54 million at the end of 2024, a 5.3% increase from 2023, and a 58.7% increase since 2014.

How much cash does Phibro Animal Health have?

In the past 10 years, Phibro Animal Health's cash and equivalents has ranged from $11.82 million in 2014 to $74.25 million in 2022, and is currently $70.61 million as of their latest financial filing in 2024.

How has Phibro Animal Health's book value per share changed over the last 10 years?

Over the last 10 years, Phibro Animal Health's book value per share changed from 0.39 in 2014 to 6.34 in 2024, a change of 1,522.6%.

Related Companies

This page (NASDAQ:PAHC) was last updated on 4/19/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Financials

Frequently Asked Questions About Phibro Animal Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Financials

Annual Income Statements for Phibro Animal Health

Quarterly Income Statements for Phibro Animal Health

Annual Cash Flow Statements for Phibro Animal Health

Quarterly Cash Flow Statements for Phibro Animal Health

Annual Balance Sheets for Phibro Animal Health

Quarterly Balance Sheets for Phibro Animal Health

Annual Metrics and Ratios for Phibro Animal Health

Quarterly Metrics and Ratios for Phibro Animal Health

Frequently Asked Questions About Phibro Animal Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools